Publication: Delayed Pressure Urticaria: A Systematic Review of Treatment Options
6
Issued Date
2020-06-01
Resource Type
ISSN
22132198
Other identifier(s)
2-s2.0-85085621364
Rights
Mahidol University
Rights Holder(s)
SCOPUS
Bibliographic Citation
Journal of Allergy and Clinical Immunology: In Practice. Vol.8, No.6 (2020), 2035-2049.e5
Suggested Citation
Kanokvalai Kulthanan, Patompong Ungprasert, Papapit Tuchinda, Leena Chularojanamontri, Norramon Charoenpipatsin, Marcus Maurer Delayed Pressure Urticaria: A Systematic Review of Treatment Options. Journal of Allergy and Clinical Immunology: In Practice. Vol.8, No.6 (2020), 2035-2049.e5. doi:10.1016/j.jaip.2020.03.004 Retrieved from: https://repository.li.mahidol.ac.th/handle/123456789/58140
Research Projects
Organizational Units
Authors
Journal Issue
Thesis
Title
Delayed Pressure Urticaria: A Systematic Review of Treatment Options
Abstract
© 2020 American Academy of Allergy, Asthma & Immunology Background: Delayed pressure urticaria (DPU) is characterized by recurrent erythematous and often painful swelling after the skin is exposed to sustained pressure. Treatment is challenging. Antihistamines, the first-line and only approved treatment, are often not effective. Objective: To systematically review the treatment options for DPU. Method: A literature search of electronic databases for all relevant articles published till April 29, 2019, was conducted using the search terms “delayed pressure urticaria” and “pressure urticaria.” This systematic review was conducted in accordance with the Preferred Reporting Items for Systematic Reviews and Meta-Analyses recommendations. Results: Twenty-one studies (8 randomized controlled trials [RCTs], 10 retrospective cohort studies, and 3 open-label prospective studies) were included. Second-generation H1 antihistamines (sgAHs) were effective in 3 RCTs. The combination of an sgAH and montelukast (2 RCTs) or an sgAH and theophylline (1 non-RCT) was more effective than the sgAH alone. The disease improved with omalizumab (4 non-RCTs), sulphones (3 non-RCTs), oral prednisolone (1 RCT and 2 non-RCTs), intravenous immunoglobulin (1 non-RCT), and gluten-free diet (1 non-RCT). There are no studies on updosing of antihistamines over standard dosage in DPU. Conclusions: Overall, the quality of studies on DPU is low. Because of the lack of other evidence, antihistamines remain the first-line therapy. Updosing of sgAHs could be considered in patients with uncontrolled symptoms on the basis of the extrapolation of evidence from chronic spontaneous urticaria, even though there is no evidence of its efficacy over standard dosage. Addition of montelukast may be considered. Omalizumab or sulphones may be used in treatment-resistant patients. High-quality DPU studies should be conducted.